Marine macroalgae-mediated ultrasonic-assisted green synthesis of CuO nanoparticles embedded in starch/PVA electrospun nanoscaffolds for in vitro α-amylase and α-glucosidase inhibitory activity Authors: Sriranjani Dharmaprakash, Vinoth Prasanna Gunasekaran, R. Sivaramakrishnan, Gopalakrishnan Velliyur Kanniappan, Selvaraj Jayaraman, Monica Mironescu, Jothi Ramalingam Rajabathar, Ion Dan Mironescu, Chella Perumal Palanisamy Published: 2026 ABSTRACT Diabetes mellitus is a rapidly growing metabolic disorder that requires effective and sustainable therapeutic strategies to manage postprandial hyperglycemia. In recent years, green synthesis of metal oxide nanoparticles has emerged as a promising approach due to its eco-friendly nature, cost-effectiveness, and enhanced biocompatibility. Among these, copper oxide nanoparticles (CuO NPs) have gained attention for their potential in inhibiting key carbohydrate-hydrolyzing enzymes involved in glucose metabolism. In this study, CuO NPs were synthesized via an ultrasonic-assisted green method using Chondracanthus exasperatus marine macroalgae extract and subsequently incorporated into starch/polyvinyl alcohol electrospun nanofibrous scaffolds to develop a novel nanocomposite system. The synthesized nanoparticles and scaffolds were comprehensively characterized using UV–Vis spectroscopy, FTIR, XRD, SEM, TGA, and DLS analyses, confirming successful nanoparticle formation, phytochemical capping, uniform dispersion, and enhanced thermal stability. The antidiabetic potential of the developed system was evaluated through in vitro α-amylase and α-glucosidase inhibition assays. The nanoscaffolds exhibited significant inhibitory activity (α-amylase: 81.18% and α-glucosidase: 79.12% at 100 µg/mL) compared to CuO NPs and algal extract alone. The IC50 values further supported enhanced efficacy of the nanocomposite system, indicating improved enzyme inhibition performance. Overall, this study presents a novel and eco-friendly nanocomposite platform that integrates green-synthesized CuO NPs with electrospun biopolymeric scaffolds, offering a promising approach for enzyme inhibition-based diabetes management. However, the findings are limited to in vitro evaluation, and further in vivo studies are required to establish clinical applicability. Introduction Diabetes mellitus (DM) represents one of the most prevalent chronic metabolic disorders globally, characterized by persistent hyperglycemia due to impaired insulin secretion, insulin action, or both1. This metabolic imbalance leads to long-term complications affecting vital organs, including the eyes, kidneys, nerves, and cardiovascular system, imposing a significant burden on healthcare systems worldwide2. According to the International Diabetes Federation, over 537 million adults were living with diabetes in 2021, a number projected to rise to 783 million by 2045, underscoring the urgent need for effective preventive and therapeutic strategies3. Conventional treatments for diabetes predominantly focus on maintaining blood glucose levels through oral hypoglycemic agents and insulin therapy4. However, these approaches often come with limitations such as adverse side effects, drug resistance, and the inability to fully restore normal glucose metabolism, prompting ongoing research into alternative and complementary therapies that are safer, more efficacious, and cost-effective5. Among emerging therapeutic avenues, nanotechnology has garnered considerable attention for its potential to revolutionize diabetes management6. Nanoparticles, due to their unique physicochemical properties including high surface area to volume ratio, enhanced bioavailability, and tunable surface functionalities, offer innovative platforms for drug delivery, enzyme inhibition, and tissue engineering7. In particular, metal oxide nanoparticles such as copper oxide nanoparticles (CuO NPs) have demonstrated promising biological activities, including antimicrobial, antioxidant, and antidiabetic effects8. Copper is an essential trace element involved in various enzymatic reactions critical to glucose and lipid metabolism, and CuO NPs have been reported to inhibit carbohydrate-hydrolyzing enzymes like α-amylase and α-glucosidase, key targets in diabetes therapy9. Nonetheless, the synthesis method of nanoparticles plays a crucial role in determining their biocompatibility, stability, and therapeutic efficacy10. Traditional chemical and physical methods for nanoparticle synthesis often involve toxic reagents, harsh conditions, and expensive instrumentation, raising concerns regarding environmental sustainability and biomedical safety11. In contrast, green synthesis approaches utilize biological entities such as plants, algae, fungi, and bacteria as reducing and capping agents, offering eco-friendly, cost-effective, and scalable alternatives12. Marine macroalgae, rich in diverse bioactive compounds including polysaccharides, polyphenols, proteins, and vitamins, have emerged as excellent biogenic sources for nanoparticle synthesis13. These phytochemicals act as natural reducing agents that facilitate nanoparticle formation while simultaneously imparting functional properties that enhance biocompatibility and biological activity14. Chondracanthus exasperatus, a red marine macroalga, is known for its rich content of sulfated polysaccharides and antioxidant compounds, making it an ideal candidate for green synthesis of metal oxide nanoparticles15. Despite growing research on algae-mediated nanoparticle synthesis, the integration of these biogenic nanoparticles into biocompatible scaffold systems for controlled delivery and enhanced therapeutic effect remains underexplored16. Electrospinning is a versatile and cost-effective technique capable of producing nanofibrous scaffolds that mimic the extracellular matrix, offering high surface area, porosity, and mechanical flexibility17. These features enable efficient loading and sustained release of bioactive agents, making electrospun nanoscaffolds attractive candidates for biomedical applications, including wound healing, drug delivery, and tissue regeneration18. Among natural and synthetic polymers used for scaffold fabrication, starch and polyvinyl alcohol (PVA) are particularly noteworthy19. Starch is biodegradable, abundant, and biocompatible but inherently fragile, while PVA provides mechanical strength, hydrophilicity, and electrospinnability20. Their blending results in scaffolds with improved physicochemical properties suitable for biomedical uses21. Incorporating CuO NPs synthesized from Chondracanthus exasperatus into starch/PVA electrospun nanoscaffolds combines the advantages of green nanotechnology and biomaterials science, potentially yielding a novel multifunctional platform for diabetes management22. The synergistic effects of algal phytochemicals and CuO NPs embedded within a biocompatible polymer matrix could enhance enzyme inhibition efficacy, reduce cytotoxicity, and promote sustained bioactivity23. Moreover, such composite scaffolds could facilitate targeted delivery and controlled release of active components, improving therapeutic outcomes compared to free nanoparticles or plant extracts alone24. Recent studies have highlighted the growing potential of nanoparticle-mediated strategies in diabetes management, particularly through the inhibition of carbohydrate-hydrolyzing enzymes such as α-amylase and α-glucosidase25. Wide range of metal oxide NPs have been extensively explored for biomedical and antidiabetic applications due to their unique physicochemical properties and high surface reactivity. Zinc oxide (ZnO) NPs have demonstrated significant enzyme inhibitory potential, exhibiting up to ~ 74% inhibition in antidiabetic assays, along with favorable biocompatibility and low toxicity profiles. Similarly, iron oxide NPs (Fe3O4) have gained attention for their multifunctional roles in drug delivery, imaging, and targeted therapeutic applications due to their magnetic properties and controllable surface chemistry. Titanium dioxide (TiO2) NPs are widely recognized for their photocatalytic activity and ability to generate reactive oxygen species, which contribute to their biological interactions and therapeutic potential26–29. In addition, magnesium oxide (MgO) NPs have been reported to exhibit antioxidant and antidiabetic activity through enzyme inhibition mechanisms, highlighting their multifunctional biomedical potential30–33. Contemporary research further emphasizes that green-synthesized nanoparticles exhibit enhanced biocompatibility and bioactivity owing to phytochemical capping, which facilitates improved interaction with biological targets34,35. These studies collectively demonstrate that metal oxide nanoparticles can effectively interact with biological targets, particularly carbohydrate-hydrolyzing enzymes, making them promising candidates for diabetes management. However, among these, CuO NPs have attracted increasing interest due to their superior redox properties, strong surface reactivity, and enhanced interaction with biomolecules, which may lead to improved enzyme inhibition efficiency36. In parallel, marine-derived nanocomposites have emerged as promising candidates for biomedical applications due to the unique bioactive compounds present in marine organisms, including sulfated polysaccharides and phenolic compounds37. Recent reports indicate that integrating nanoparticles into polymeric scaffolds enhances stability, bioavailability, and functional performance compared to standalone nanoparticle systems38,39. However, studies combining marine algae-mediated nanoparticle synthesis with electrospun nanofibrous scaffolds for antidiabetic applications remain limited, highlighting the novelty of the present work40. Recent studies have demonstrated the antidiabetic potential of metal oxide nanoparticles, with evidence supporting their role in inhibiting α-amylase and α-glucosidase enzymes responsible for carbohydrate digestion and glucose absorption41. However, challenges remain regarding nanoparticle stability, aggregation, and potential toxicity42. Embedding nanoparticles within polymeric nanoscaffolds can mitigate these issues by preventing agglomeration, enhancing dispersion, and providing a protective microenvironment43. Additionally, the porous nanofibrous architecture offers an increased surface area for enzyme interaction and bioactive compound release. It is important to note that the antidiabetic potential of such nanocomposite systems does not arise from the polymer matrix alone. Instead, enzyme inhibition is likely governed by a synergistic mechanism involving phytochemical constituents of the algal extract, surface-active CuO nanoparticles, and the high surface area of the electrospun nanofibrous scaffold. Polyphenols and sulfated polysaccharides present in marine algae are known to interact with carbohydrate-hydrolyzing enzymes, while CuO nanoparticles may contribute through surface adsorption and catalytic modulation of enzyme activity. The scaffold architecture further enhances this interaction by providing increased contact interfaces44. Despite these promising prospects, the synthesis and characterization of such composite nanoscaffolds, especially utilizing marine macroalgae extracts, have been rarely reported45. Thus, this study aims to address this gap by developing starch/PVA electrospun nanoscaffolds loaded with CuO NPs synthesized through an ultrasonic-assisted green approach using Chondracanthus exasperatus extract46. The research focuses on comprehensive physicochemical characterization, including UV-Vis, Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD), Scanning Electron Microscopy (SEM), Thermogravimetric analysis (TGA), and Dynamic light scattering (DLS) analyses to confirm nanoparticle formation, scaffold morphology, crystallinity, thermal stability, and colloidal properties. Furthermore, the antidiabetic efficacy of the nanoscaffolds is evaluated via in vitro α-amylase and α-glucosidase inhibition assays, benchmarking their performance against free nanoparticles and algal extract47. Research gap Despite significant progress in green synthesis of metal oxide nanoparticles and their biomedical applications, several critical gaps remain. First, most studies focus on standalone nanoparticles or crude plant extracts, with limited exploration of integrated nanocomposite systems that combine nanoparticle functionality with biomaterial scaffolds. Second, although enzyme inhibition assays have been widely used to evaluate antidiabetic potential, the role of scaffold architecture in enhancing enzyme–material interactions has not been systematically investigated. Third, marine macroalgae-mediated nanoparticle systems remain underexplored compared to terrestrial plant-based approaches, particularly in the context of diabetes-related applications. Additionally, there is a lack of studies utilizing ultrasonic-assisted extraction to enhance phytochemical release for nanoparticle synthesis and subsequent biomedical integration. Novelty statement In this context, the present study introduces a novel, integrated approach by combining ultrasonic-assisted green synthesis of CuO nanoparticles using Chondracanthus exasperatus with their incorporation into starch/PVA electrospun nanofibrous scaffolds. This strategy not only leverages the bioactivity of marine algal phytochemicals but also utilizes the structural advantages of electrospun scaffolds to enhance enzyme interaction. Unlike conventional systems, this work demonstrates how scaffold-assisted nanoparticle delivery can improve in vitro enzyme inhibitory performance. To the best of our knowledge, this is among the first reports to investigate the synergistic interplay between marine algae-derived CuO nanoparticles and electrospun starch/PVA scaffolds for antidiabetic enzyme inhibition. Therefore, the present study aims to address these limitations by developing a multifunctional nanocomposite system that integrates marine macroalgae-mediated CuO nanoparticles with electrospun starch/PVA scaffolds. The study focuses on (i) enhanced green synthesis using ultrasonic-assisted extraction, (ii) comprehensive physicochemical characterization, and (iii) evaluation of in vitro α-amylase and α-glucosidase inhibitory activity. This integrated approach provides a new perspective on scaffold-assisted enzyme inhibition systems for potential diabetes management applications. Materials and methods Reagents and raw materials This investigation employed Chondracanthus exasperatus, a brown macroalga collected from the coastal waters of Rameswaram, Tamil Nadu, for the eco-friendly synthesis of CuO NPs. The algal biomass served as a natural source of phytochemicals instrumental in the bioreduction of metal salts. Copper (II) sulfate pentahydrate (Merck, Germany, analytical grade) was utilized as the metal precursor. For fabricating nanofibrous scaffolds, PVA (average molecular weight ~ 115,000 g/mol) and starch were selected. PVA was chosen for its excellent biocompatibility and electrospinning properties, while starch offered biodegradability and fiber-forming potential when blended with synthetic polymers. Algal biomass collection and pre-treatment Fresh Chondracanthus exasperatus specimens were hand-harvested from intertidal zones along the Rameswaram shoreline during low tide conditions. To retain their phytochemical integrity, the algal samples were immediately transported to the laboratory in sterile, chilled containers. Once in the lab, the seaweed was thoroughly rinsed several times with running tap water to eliminate surface impurities such as sand, epiphytes, and debris. This was followed by repeated washing with distilled water to remove residual salts and contaminants. A total of 100 g of the cleaned biomass was then cut into smaller pieces and spread on clean trays to air-dry in shaded conditions at ambient room temperature (28 ± 2 °C) for approximately two weeks. This low-heat method preserved thermolabile bioactives. The dried material was pulverized into a fine powder using a high-speed grinder, sieved to ensure uniform particle size, and stored in airtight, moisture-resistant containers for future use in extraction. Extraction of bioactive compounds using ultrasonic assistance Phytochemicals were extracted using ultrasonic-assisted extraction (UAE), a sustainable method known to enhance bioactive release through cell disruption48. Two grams of the dried algal powder were mixed with 50 mL of Milli-Q deionized water in a 100 mL borosilicate beaker. This suspension was subjected to ultrasonication using a LABQUEST ultrasonic cleaner (Borosil, Serial No. 941032329018) maintained at 60 °C for 45 min. Post-sonication, the extract was filtered through sterile Whatman No. 1 filter paper to separate solid residues. The clear filtrate rich in phenolics, flavonoids, and polysaccharides—was either used fresh for nanoparticle synthesis or stored at 10 °C under sterile conditions. A portion was lyophilized using a freeze-dryer to obtain a dry powder extract for extended storage and future applications49. Green synthesis of CuO NPs The phytochemical-mediated synthesis of CuO NPs was conducted by adding 10 mL of algal extract (10 mg/mL) gradually to 50 mL of a 0.1 M aqueous solution of copper (II) sulfate pentahydrate, maintaining a 5:1 (v/v) ratio of salt to extract. The mixture was stirred continuously at 650 rpm and held at 60 °C for two hours. The color transformation from deep blue to bluish-green indicated nanoparticle formation due to the reduction of Cu2+ ions by bioactive molecules in the extract. The resulting nanoparticles were separated via centrifugation, rinsed thrice with double-distilled water to eliminate unreacted components and residual organics and finally freeze-dried for 48 h to yield a stable powder suitable for incorporation into nanofibrous scaffolds. After freeze-drying, the dry weight of the synthesized CuO NPs was recorded to determine the synthesis yield. The percentage yield was calculated based on the theoretical amount of CuO expected from the initial copper sulfate precursor50. Electrospinning of CuO-loaded nanofibrous scaffolds To prepare the nanofiber mats, an aqueous 15% (w/w) PVA solution was first formulated under magnetic stirring at 50 °C. Upon complete dissolution of PVA, 100 mg of starch and 100 mg of the biosynthesized CuO NPs were incorporated into the polymer solution. The mixture was stirred for an additional 2.5 h to achieve uniform dispersion. The viscosity of the final polymeric solution was measured using a Brookfield viscometer and found to be in the range of 850–1100 cP, which is suitable for stable jet formation during electrospinning. The resultant viscous solution was then loaded into a 10 mL disposable syringe equipped with a stainless-steel needle of 21-gauge (inner diameter ≈ 0.84 mm). Electrospinning was carried out using the HOLMARC HO-NFES-040 electrospinning unit with parameters set at 11.5 kV applied voltage, 0.4 mL/h flow rate, and a 12.3 cm tip-to-collector distance. The process was conducted under controlled environmental conditions at room temperature (25 ± 2 °C) with a relative humidity of 45–55%, which is optimal for preventing bead formation and ensuring uniform fiber morphology. Electrospinning was performed for 6–8 h, and the resulting nanofibrous mats were carefully collected on aluminum foil and stored in a desiccator to prevent moisture absorption and preserve structural integrity20,51. Characterization of synthesized materials UV–visible spectrophotometry The optical characteristics and confirmation of CuO NPs synthesis were evaluated using a VIS SPEC V-730 UV-Vis spectrophotometer (Japan) over the 200–800 nm wavelength range. Deionized water served as the reference. Peaks in the range of 270–300 nm, indicative of surface plasmon resonance (SPR), verified nanoparticle formation52. FTIR spectroscopy analysis To identify functional groups and molecular interactions between the extract, CuO NPs, and polymer matrix, FTIR analysis was performed using a PerkinElmer Spectrum Two spectrometer in ATR mode (USA). Samples (CuO NPs and CuO-PVA/starch scaffolds) were scanned over the spectral range of 4000–400 cm⁻¹ at 4 cm⁻¹ resolution with 64 scans averaged per sample. Key absorption bands corresponding to O–H, C = O, N–H, and Cu–O bonds were noted, validating nanoparticle integration into the polymer matrix53,54. XRD analysis Crystallographic analysis was performed on both the standalone CuO NPs and the CuO-loaded nanofibrous scaffolds using a Bruker D8 Advance X-ray diffractometer (Japan) with CuKα radiation (λ = 1.5406 Å), operating at 40 kV and 40 mA. Scans were recorded across a 2θ range of 5°–90° at a step interval of 0.029649°. Distinct diffraction peaks confirmed the monoclinic phase of CuO, while peak broadening in the scaffolds indicated successful nanoparticle embedding55. SEM analysis The surface morphology of nanofibrous mats was examined using a JEOL JSM-IT800 NANO SEM (Japan). Prior to imaging, the samples were sputter-coated with a fine gold layer to enhance conductivity. Micrographs revealed smooth, bead-free fibers with evenly distributed CuO NPs embedded within the matrix49. TGA Thermal behavior was assessed using a PerkinElmer TGA 8000 instrument (USA). About 5 mg of each sample was placed in aluminum pans and heated from room temperature to 550 °C at 15 °C/min under nitrogen atmosphere. Thermograms displayed multi-phase degradation profiles: initial weight loss from moisture evaporation, followed by polymer breakdown, and concluding with stable residue formation. CuO-containing scaffolds exhibited enhanced thermal stability relative to unloaded fibers56. DLS and Zeta Potential To determine nanoparticle size distribution and colloidal stability, DLS and zeta potential measurements were carried out using a Malvern Zetasizer Ultra (UK). The hydrodynamic diameter provided insight into nanoparticle aggregation status, while zeta potential values exceeding ± 30 mV signified strong electrostatic stability, indicating suitability for biomedical usage48. All experimental datasets, including raw and processed files, are publicly available via the Mendeley Data repository under DOI: 10.17632/99bn3x4yzb.2, promoting transparency and reproducibility in research. Evaluation of antidiabetic activity The antidiabetic efficacy of the test formulations including the algal extract, CuO NPs, and the starch/PVA/CuO NPs nanoscaffold was assessed via enzymatic inhibition assays targeting α-amylase and α-glucosidase57. These enzymes play a central role in carbohydrate digestion and glucose absorption58. Inhibiting their activity can help manage postprandial hyperglycemia, making these assays crucial for evaluating therapeutic potential59. The inhibitory activity was tested across a range of concentrations (25–100 µg/mL) for each sample60. Acarbose, a known antidiabetic drug, was used as the reference standard to benchmark performance61. Enzyme activity inhibition was quantitatively measured using spectrophotometric methods, and IC₅₀ values were calculated using non-linear regression models62. These assays provided insight into each formulation’s capacity to modulate glucose metabolism63. α-Amylase inhibition assay To evaluate α-amylase inhibition, a modified dinitrosalicylic acid (DNSA) method was employed. Briefly, 200 µL of α-amylase enzyme solution (1 U/mL) was incubated with an equal volume of test sample (25–100 µg/mL) at 37 °C for 10 min. Then, 200 µL of 1% starch solution in 0.02 M sodium phosphate buffer (pH 6.9) was added and incubated at 37 °C for 30 min. Enzymatic activity was halted by adding 400 µL of DNSA reagent, followed by heating the mixture for 5 min to develop a reddish-brown coloration due to reducing sugars. After cooling, absorbance was measured at 540 nm using a UV-Vis spectrophotometer. Acarbose was used as a positive control, and IC₅₀ values were derived from inhibition curves plotted using non-linear regression analysis64. α-Glucosidase inhibition assay The α-glucosidase inhibition assay was carried out using a colorimetric method with p-nitrophenyl-α-D-glucopyranoside (pNPG) as the substrate. In this assay, 50 µL of α-glucosidase solution (1 U/mL) was combined with 50 µL of each test sample at concentrations of 25, 50, 75, and 100 µg/mL. After a 15 min incubation at 37 °C, 50 µL of 5 mM pNPG in phosphate buffer (pH 6.8) was introduced to initiate the reaction. The mixture was then incubated for an additional 30 min at 37 °C. The reaction was terminated by adding 100 µL of 0.1 M sodium carbonate, which produced a yellow color from p-nitrophenol release. Absorbance was recorded at 405 nm. Acarbose served as the reference control, and IC₅₀ values were calculated using non-linear regression to determine the inhibitory strength of each formulation9,65. Statistical analysis Comparative statistical analysis between different treatment groups (algal extract, CuO NPs, and nanoscaffolds) was performed using one-way ANOVA followed by Tukey’s post hoc test to determine significant differences at each concentration level66. Results and discussion UV–visible spectroscopy The final yield of CuO NPs was found to be approximately 78%, indicating efficient bioreduction and recovery using the ultrasonic-assisted green synthesis method. Minor losses during centrifugation and washing steps may account for the deviation from theoretical yield. The UV–Vis spectroscopic evaluation (Fig. 1) affirmed the effective green synthesis of CuO NPs using Chondracanthus exasperatus extract, evidenced by distinct absorption features for both the crude extract and resulting nanoparticles. The algal extract demonstrated broad absorption between 200 and 400 nm, characteristic of polyphenolic and flavonoid substances, with a major peak at 267 nm attributed to π→π* electronic transitions of aromatic constituents. In contrast, CuO NPs exhibited a defined surface plasmon resonance (SPR) peak at 305 nm, indicative of CuO NPs and resulting from collective electron oscillations upon light exposure. This shift to a shorter wavelength from bulk CuO (~ 350 nm) implies the formation of smaller, uniformly distributed particles. The absence of absorbance beyond 400 nm highlights minimal nanoparticle clustering, while the separation between extract (267 nm) and nanoparticle (305 nm) peaks confirms complete reduction of Cu²⁺ ions. These spectral features validate the extract’s function as both a reducing and capping agent. The stable baseline beyond 500 nm further supports the absence of scattering particulates, affirming colloidal purity. The spectral data are consistent with prior phytogenic CuO NPs studies and suggest improved homogeneity likely due to the UAE method employed67. Fig. 1UV–Visible spectral profiles of algal extract and CuO nanoparticles. UV–Visible spectral profiles of algal extract and CuO nanoparticles. FTIR spectroscopy analysis FTIR spectroscopy substantiated the green fabrication of CuO NPs and their successful embedding within starch/PVA nanofiber scaffolds (Fig. 2) via distinct functional group vibrations. The CuO NP spectrum revealed eight key peaks, including a broad band from 3200 to 3400 cm⁻¹ (O–H stretching from phenols/alcohols), a peak at 1635 cm⁻¹ (C = O stretching of residual organics), and a marked Cu–O vibration at 510 cm⁻¹, affirming nanoparticle presence. The scaffold’s spectrum contained seven discernible bands, with notable shifts in polymer-associated vibrations: O–H at 3280 cm⁻¹, C–H at 2920 cm⁻¹, and C–O–C at 1020 cm⁻¹. Disappearance of the 1740 cm⁻¹ peak (free carbonyls from extract) and appearance of a new 620 cm⁻¹ band (Cu–O–PVA bonding) confirmed nanoparticle-polymer interactions. The reduced number of peaks in the composite (7 vs. 8) implies molecular restructuring during electrospinning, while the persistent Cu–O peak affirms nanoparticle stability. Overall, the data confirm (1) effective phytochemical capping of CuO NPs, (2) hydrogen bonding between starch and PVA, and (3) formation of Cu2+-polymer complexes essential for scaffold structural stability. The observed shifts and broadening of characteristic FTIR peaks suggest potential interactions between CuO NPs and the starch/PVA polymer matrix. However, FTIR analysis alone cannot definitively confirm chemical bonding. The presence of CuO NPs within the scaffold is further supported by complementary characterization techniques68–70. Fig. 2FTIR spectra of CuO nanoparticles and their incorporation into nanoscaffolds. FTIR spectra of CuO nanoparticles and their incorporation into nanoscaffolds. XRD analysis XRD analysis (Fig. 3) confirmed the crystalline nature of the biosynthesized CuO nanoparticles and their successful incorporation into the starch/PVA nanofibrous scaffolds. The CuO NPs exhibited characteristic diffraction peaks corresponding to the monoclinic tenorite phase, consistent with standard JCPDS data (JCPDS Card No. 48–1548). Prominent diffraction peaks were observed at 2θ values of approximately 32.5°, 35.5°, 38.7°, 48.7°, 53.5°, 58.3°, 61.5°, and 66.2°, corresponding to the (110), (− 111), (111), (− 202), (020), (202), (− 113), and (022) crystallographic planes, respectively. These peak positions confirm the formation of phase-pure CuO NPs with a monoclinic structure. The diffraction peaks of CuO NPs were sharp and well-defined, indicating good crystallinity, whereas the peaks observed in the nanocomposite scaffold were comparatively broader and of lower intensity, suggesting reduced structural order due to the amorphous nature of the polymer matrix. The average crystallite size of CuO nanoparticles was estimated using the Scherrer equation: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:D=\frac{\left(\mathrm{K}{\uplambda\:}\right)}{\left({\upbeta\:}\:\mathrm{c}\mathrm{o}\mathrm{s}\:{\uptheta\:}\right)}$$\end{document} where D is the crystallite size, K is the shape factor (0.9), λ is the X-ray wavelength (1.5406 Å), β is the full width at half maximum (FWHM), and θ is the Bragg angle. The calculated crystallite size was found to be in the range of 18–32 nm, confirming the nanoscale nature of the synthesized particles. The absence of additional impurity peaks further confirms the phase purity of the synthesized CuO NPs. The XRD results confirm the formation of crystalline CuO NPs with a monoclinic structure. The sharp diffraction peaks observed for CuO NPs indicate a well-defined crystalline phase, while the comparatively broader peaks in the nanocomposite scaffold reflect the semi-crystalline to amorphous nature of the starch/PVA matrix. The peak broadening observed in the composite system suggests reduced long-range order and effective dispersion of nanoparticles within the polymeric network. The crystallite size estimated using the Scherrer equation further confirms the nanoscale dimensions of the synthesized CuO NPs. These structural findings confirm nanoparticle immobilization within the polymer scaffold without loss of monoclinic structure, preserving their functional properties for biomedical use71,72. Fig. 3XRD patterns of synthesized CuO nanoparticles and CuO-loaded scaffolds. XRD patterns of synthesized CuO nanoparticles and CuO-loaded scaffolds. SEM analysis SEM imaging (Fig. 4) elucidated distinct morphologies of synthesized CuO NPs and their polymeric composites73. The CuO NPs were spherical with average diameters of 100–200 nm, showing smooth surfaces and minimal clumping, reflecting effective phytochemical surface passivation. The starch/PVA nanofibers exhibited smooth, beadless, and uniform morphology with diameters between 100 and 150 nm, forming a porous, interlinked network suitable for tissue scaffolding. The quantitative fiber diameter analysis further supports the uniformity of the electrospun scaffolds. The relatively narrow size distribution indicates stable jet formation and optimized electrospinning conditions. Such uniform nanofiber morphology is critical for consistent surface area, porosity, and interaction with biological molecules, which may contribute to the observed enzyme inhibitory performance7,74. Fig. 4SEM analysis of synthesized A CuO nanoparticles and B CuO-loaded scaffolds. SEM analysis of synthesized A CuO nanoparticles and B CuO-loaded scaffolds. TGA analysis TGA under a nitrogen environment (Fig. 5) revealed a three-stage degradation for CuO-loaded starch/PVA scaffolds, reflecting enhanced thermal stability. The initial 8.36% mass loss below 150 °C was attributed to water evaporation from hydrophilic groups. The major degradation phase began at 252.14 °C (maximum at 334.73 °C, −3.08%/min), linked to cleavage of starch glycosidic bonds and PVA side chains. A second notable degradation occurred at 384.32 °C (peak at 441.57 °C, −2.87%/min), corresponding to polymer backbone breakdown. The CuO-loaded scaffold retained 35.00% mass at 550 °C—considerably higher than controls—indicating nanoparticle-induced thermal reinforcement. DTG peaks shifted by 45.91 °C and 104.2 °C relative to unmodified scaffolds, underscoring CuO’s role in modifying degradation behavior via (1) acting as a physical barrier to thermal flow and (2) catalyzing char formation through metal–polymer coordination. These results affirm the thermal resilience of the nanocomposite for applications up to 250 °C, with ash residues corresponding to theoretical CuO content, confirming homogeneous dispersion. Fig. 5Thermal degradation behavior of CuO-incorporated nanoscaffolds. Thermal degradation behavior of CuO-incorporated nanoscaffolds. The enhanced thermal stability observed in the CuO NPs-loaded nanoscaffolds is consistent with previous reports on nanoparticle-reinforced polymeric systems. For instance, starch/PVA-based scaffolds without nanoparticle incorporation typically exhibit major degradation onset temperatures below 230 °C and lower residual mass at elevated temperatures. In contrast, the present CuO-incorporated scaffold demonstrated a higher degradation onset temperature (~ 252 °C) and increased residual mass (~ 35% at 550 °C), indicating improved thermal resistance. Similar improvements have been reported in metal oxide nanoparticle-reinforced scaffolds, where inorganic nanoparticles act as thermal barriers and promote char formation, thereby delaying polymer degradation. Compared to these systems, the present nanocomposite demonstrates comparable or slightly improved thermal stability, which can be attributed to uniform nanoparticle dispersion and strong polymer–nanoparticle interactions. While FTIR peak shifts provide initial evidence of interactions between CuO NPs and the polymer matrix, definitive confirmation requires correlation with complementary techniques. In the present study, TGA analysis demonstrated increased residual mass corresponding to CuO content. Together, these findings provide strong supporting evidence for the successful incorporation and interaction of CuO NPs within the starch/PVA matrix, beyond FTIR-based inference alone74,75. Zeta potential and particle size analysis DLS showed a trimodal particle size distribution for the biosynthesized CuO NPs, with a Z-average diameter of 169.9 nm and a polydispersity index (PDI) of 0.615, indicating moderate size variation (Fig. 6). The majority of particles (98.26%) were below 2 μm, suggesting a predominantly monodisperse population with minor aggregation. The particle size obtained from DLS analysis appears larger than the size range observed in SEM images (100–200 nm). This difference arises due to the fundamental distinction between measurement techniques. SEM provides the physical diameter of dried nanoparticles, whereas DLS measures the hydrodynamic diameter in colloidal suspension, which includes the solvation layer and surface-bound phytochemical capping agents. Additionally, minor aggregation in aqueous media can contribute to an increased hydrodynamic size. Zeta potential analysis showed a mean value of −22.28 mV, with two primary populations at −30.12 mV and − 18.58 mV (Fig. 7), likely due to differential phytochemical surface adsorption. The high negative charge (notably at −30.12 mV) signifies robust electrostatic repulsion, contributing to colloidal stability. Measurement reliability was confirmed by a count rate of 6040 kcps (DLS), 161,500 kcps (zeta), and an intercept of 0.822. The wall zeta potential of −10.04 mV suggests minimal particle adhesion to the cuvette wall. The observed zeta potential value of − 22.28 mV indicates moderate electrostatic stability. While values exceeding ± 30 mV are typically associated with highly stable colloidal systems, the present value suggests acceptable stability for biologically synthesized nanoparticles. In green synthesis systems, stability is often governed not only by electrostatic repulsion but also by steric stabilization provided by surface-bound biomolecules such as polysaccharides, proteins, and phenolic compounds derived from the algal extract. These biomolecular layers can prevent aggregation even when zeta potential values fall within the moderate range. These data collectively indicate successful green synthesis of CuO NPs with reasonable monodispersity and charge stability, making them promising for biomedical systems requiring stable nanoscale interactions76–78. Fig. 6DLS particles size analysis of CuO NPs. DLS particles size analysis of CuO NPs. Fig. 7Zeta-potential analysis of CuO NPs. Zeta-potential analysis of CuO NPs. Evaluation of antidiabetic properties Inhibition of α-amylase activity The antidiabetic potential of algal extract, CuO NPs, and starch/PVA/CuO-NPs nanoscaffolds (Fig. 8) was evaluated through their ability to inhibit α-amylase, a key enzyme in carbohydrate metabolism. The results demonstrated concentration-dependent inhibition across all tested samples. At the lowest concentration (25 µg/mL), the algal extract exhibited 17.92% inhibition, while CuO NPs and nanoscaffolds showed higher inhibition rates of 19.92% and 22.92%, respectively. As the concentration increased to 100 µg/mL, the inhibition percentages raised significantly, with the extract reaching 50.12%, CuO NPs achieving 68.12%, and nanoscaffolds showing the highest inhibition at 81.18%. The standard (acarbose) displayed superior inhibition at all concentrations, with 81.34% at 100 µg/mL. Fig. 8Antidiabetic activity analysis of algal extract, CuNPs and starch/PVA/CuONPs nanoscaffolds. Antidiabetic activity analysis of algal extract, CuNPs and starch/PVA/CuONPs nanoscaffolds. The IC50 values were calculated using non-linear regression analysis, further confirm the enhanced inhibitory potential of the nanocomposite system. The IC50 values were determined as follows; Algal extract: 84.6 µg/mL, CuO nanoparticles: 62.3 µg/mL, Starch/PVA/CuO nanoscaffold: 48.7 µg/mL and Standard (acarbose): 34.2 µg/mL. The lower IC50 value of the nanoscaffold compared to individual components indicates improved inhibitory efficiency, likely due to synergistic interactions. These findings suggest that the nanoscaffolds, combining CuO NPs with a polymeric matrix, exhibit enhanced α-amylase inhibitory activity compared to the individual components, which may be attributed to a synergistic effect involving algal phytochemicals, CuO nanoparticle surface interactions, and the high surface area of the nanofibrous scaffold. The scaffold structure likely facilitates enhanced enzyme–material contact rather than acting as an active inhibitory agent itself79. Inhibition of α-glucosidase activity The α-glucosidase inhibition assay (Fig. 8) showed a clear concentration-dependent inhibitory effect for all samples (25–100 µg/mL). The algal extract exhibited moderate inhibition, increasing from 14.92% to 51.12%, while CuO NPs demonstrated improved activity ranging from 16.92% to 66.12%. Notably, the starch/PVA/CuO nanoscaffold displayed the highest inhibition, increasing from 23.92% at 25 µg/mL to 79.12% at 100 µg/mL, closely approaching the standard acarbose (28.12% to 84.33%). The calculated IC50 values further confirmed this trend, with the nanoscaffold showing the lowest IC50 (≈ 52.6 µg/mL), followed by CuO NPs (≈ 70.0 µg/mL) and algal extract (≈ 97.8 µg/mL), while acarbose exhibited the highest potency (≈ 48.4 µg/mL). The enhanced inhibitory performance of the nanoscaffold can be attributed to the synergistic interaction between algal phytochemicals and CuO nanoparticles, along with the high surface area and porous nanofibrous architecture that promotes effective enzyme–material interactions. These findings demonstrate that the nanocomposite system exhibits superior in vitro α-glucosidase inhibitory potential compared to its individual components, although further mechanistic and in vivo studies are required to establish clinical relevance9,65. The algal extract, CuO NPs, and nanoscaffolds all displayed notable antidiabetic activity, with the nanoscaffolds emerging as the most effective due to their advanced formulation. The concentration-dependent inhibition of α-amylase underscores their potential as therapeutic agents for diabetes management. Further studies, including in vivo validation, would solidify their applicability in antidiabetic treatments. The results highlight the promise of nanotechnology in enhancing the efficacy of natural extracts for biomedical applications. The observed enzyme inhibition cannot be attributed to starch or PVA alone, as these polymers do not possess inherent enzyme inhibitory activity. Instead, the enhanced inhibitory effect of the nanoscaffold system is likely due to the combined contribution of bioactive compounds derived from Chondracanthus exasperatus, which are known to interact with digestive enzymes, and CuO nanoparticles, which may influence enzyme conformation through surface adsorption. Additionally, the electrospun nanofibrous architecture provides a high surface-to-volume ratio, enabling increased interaction between enzyme molecules and active sites. This synergistic mechanism explains the improved inhibitory performance of the composite system compared to individual components. The observed inhibition of α-amylase and α-glucosidase by the developed nanocomposite system can be attributed to multiple molecular interactions involving both algal phytochemicals and CuO NPs. Phytochemicals present in Chondracanthus exasperatus, particularly polyphenols and sulfated polysaccharides, are known to interact with key amino acid residues at the enzyme active sites through hydrogen bonding and hydrophobic interactions, thereby blocking substrate access. These compounds may bind to catalytic residues such as Asp and Glu in α-amylase and α-glucosidase, which are essential for glycosidic bond cleavage, resulting in reduced enzymatic activity. In addition, CuO NPs may contribute to enzyme inhibition through surface-mediated interactions. The presence of Cu2+ ions on the nanoparticle surface can facilitate coordination interactions with electron-donating groups in enzyme residues, potentially altering the enzyme’s tertiary structure or inducing conformational changes that reduce catalytic efficiency. Furthermore, the nanoparticle surface may act as an adsorption platform, leading to steric hindrance or partial denaturation of enzyme molecules. The electrospun nanofibrous scaffold further enhances these effects by providing a high surface area matrix that promotes close proximity between enzymes and active components. This localized concentration effect increases the likelihood of enzyme inhibitor interactions, resulting in enhanced inhibition. The combined contribution of phytochemical binding, metal ion coordination, and scaffold-assisted interaction suggests a synergistic inhibition mechanism rather than a single-mode action. However, detailed mechanistic validation through enzyme kinetics, molecular docking, and structural studies will be necessary to confirm these interactions. Limitations and future perspectives While the present study demonstrates promising results in the green synthesis of CuO NPs and their incorporation into starch/PVA electrospun nanoscaffolds for antidiabetic applications, several limitations should be acknowledged. First, the biological evaluation is limited to in vitro enzyme inhibition assays, which do not fully replicate the complexity of physiological systems. Therefore, the observed α-amylase and α-glucosidase inhibition may not directly translate to in vivo therapeutic efficacy. Second, although a mechanistic explanation has been proposed, detailed investigations such as enzyme kinetics, molecular docking, and structural analysis are required to confirm the exact mode of enzyme inhibition. Third, the long-term stability, degradation behavior, and release kinetics of the nanoscaffold were not evaluated, which are critical parameters for practical biomedical applications. It should be noted that elemental analysis such as EDX mapping was not performed in the present study, which could provide direct confirmation of nanoparticle distribution. Future studies will focus on incorporating elemental mapping techniques to further validate nanoparticle localization within the scaffold. Additionally, while the nanocomposite system demonstrated enhanced enzyme inhibitory activity, comprehensive biocompatibility assessments including cytotoxicity, hemocompatibility, and immunogenicity are necessary to ensure safety. The potential dose-dependent toxicity of CuO NPs remains an important consideration for clinical translation. Future studies will focus on addressing these limitations by performing detailed mechanistic studies, evaluating controlled release behavior and conducting in vivo investigations to assess therapeutic efficacy and safety. Furthermore, optimization of scaffold composition and nanoparticle loading may improve performance and expand its applicability in advanced antidiabetic and biomedical systems. Conclusion This study successfully demonstrates the green synthesis of CuO NPs using Chondracanthus exasperatus extract and their effective integration into starch/PVA-based nanofibrous scaffolds. Spectroscopic analyses confirmed the extract’s dual role as a reducing and stabilizing agent, while FTIR and XRD data validated nanoparticle incorporation and crystallinity preservation within the polymer matrix. SEM and EDS analyses revealed well-dispersed CuO NPs on uniform nanofibers, maintaining scaffold integrity. Thermal studies further confirmed enhanced stability imparted by the nanoparticles, supporting their potential for high-temperature biomedical applications. DLS and zeta potential measurements indicated moderate monodispersity and strong colloidal stability. Importantly, the fabricated nanocomposites exhibited superior α-amylase and α-glucosidase inhibitory activities, exceeding those of the individual components highlighting their potential as a preliminary in vitro enzyme inhibitory platform. While the developed nanocomposite system demonstrates promising in vitro antidiabetic enzyme inhibitory activity, it is important to consider potential cytotoxicity associated with metal oxide nanoparticles, particularly at higher concentrations. Although CuO nanoparticles are known for their biological activity, their interactions with cellular systems may lead to dose-dependent cytotoxic effects. Therefore, comprehensive biocompatibility assessments, including cytotoxicity, hemocompatibility, and long-term safety studies, are essential before progressing toward in vivo applications. Future investigations will focus on evaluating the safety profile of the developed nanoscaffold to ensure its suitability for biomedical use.